Drug manufacturers are developing
new class of compounds called Rho-kinase inhibitors for the treatment of
glaucoma. Rho-kinase pathway is an integral part of cellular functions such as
contraction of vascular smooth muscle cells, organization of the actin
cytoskeleton, cell adhesion and motility and gene expression. These inhibitors
are different from widely used prostaglandin analogs because they target the
outflow through trabecular meshwork rather than the uveoscleral outflow.
Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to
30% with duration of action of 10 to 12 hours, which is more effective than the
previous generation of drugs for this condition. Major Rho-kinase inhibitors
being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and
BOL-303259-X.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL OPHTHALMOLOGY DRUGS MARKET TO GROW TO $38
BILLION BY
2021
North America was the largest
region in the ophthalmology drugs market in 2017, accounting for one-third of
the market share. This was mainly due to the high per capita healthcare
expenditure and access to advanced eye care facilities in the region.
Order the report at https://www.thebusinessresearchcompany.com/report/ophthalmology-drugs-global-market-report-2018
The chart below shows the
year-on-year growth of global ophthalmology drugs market during 2017 – 2021
According to The Business Research
Company’s Consultant, Nitin Gianchandani, drug manufacturers are increasingly
developing ophthalmic drugs with anti-inflammatory agents to ease patient
treatment for dry eye syndrome. Anti-inflammatory
drugs are widely used for the treatment of the inflammation produced by the
disease with the topical corticosteroid drops being the most common therapy.
Corticosteroids can rapidly and effectively relieve the symptoms and signs of
moderate or severe dry eye. However, prolonged usage of corticosteroids has
seen to produce side effects that include risk of bacterial or fungal
infection, elevated intraocular pressure and cataract formation. As a
consequence, NSAIDs are increasingly being used as dry eye treatment instead of
steroids because of their non-severe side effects. For instance, Aciex
Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which
decrease ocular discomfort.
Download a sample of the report
at:
Novartis AG was the largest competitor in the ophthalmology drugs market, with revenues
of $6.3 billion for the financial year 2016. Novartis’
growth strategy is to focus on strengthening its ophthalmology pipeline through
acquisitions. In December 2016, the company acquired pharmaceutical company
Encore Vision, Inc. that develops treatment for presbyopia, an ophthalmologic
disorder. In addition, Novartis is focusing on licensing new products to
enhance its ophthalmology pipeline. For instance, in April 2017, it entered
into a deal with Boston-based biopharma company, Lubris LLC., to in-license its
ECF843 compound that is been developed for the treatment of dry eye syndrome
(DES).
The ophthalmology drugs market
covers drugs that are used in the treatment of eye related diseases such as
refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and
macular degeneration. Some of the major ophthalmic drugs include Eylea,
Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The market numbers in this
briefing cover pharmaceutical (drug) treatments and do not cover biologic
treatments for these conditions which are included in a separate briefing.
Ophthalmology
Drugs Global Market Report 2018 is a detailed report giving a unique insight
into this market. The report is priced at $4000 for an individual user. To use
across your office, the price is $6000 and $8000 if you wish to use across a
multinational company.
About The Business Research Company:
Visit TheBusinessResearchCompany.com,
mail info@tbrc.info or call +447443439350 or
+918897263534 or +919160996838 for more information on this and many other
titles.
The Business Research Company is a
market research and intelligence company, which excels in company, market and
consumer research.
It has research professionals at its
offices in the UK, India and the US as well a network of trained researchers
globally. It has specialist consultants in a wide range of industries including
manufacturing, healthcare, chemicals and technology.
The Business Research Company's
management has more than 20 years of varied business research experience. They
have delivered hundreds of research projects to the senior management of some
of the world's largest organizations.
Contact Information:
The
Business Research Company
Europe:
+44 207 1930 708
Asia:
+91 8897263534
Americas:
+1 315 623 0293
Email: info@tbrc.info
No comments:
Post a Comment